Zacks Investment Research is among several outlets reporting that Pfizer Inc. intends to drop its plans to develop treatments for Alzheimer’s and Parkinson’s disease, resulting in the elimination of 300 positions from the company’s neuroscience discovery and early development programs.
Alzheimer’s has been a highly challenging area, according to Zacks, which cited Alzheimer’s Association and clinicaltrials.gov data indicating that from 2002-2012, a total of 244 drugs were tested for Alzheimer’s, but only one succeeded and received FDA approval.
To read the Zacks report, click here…
Filed Under: Drug Discovery
